Phase 3 N=635 Relapse Prevention Study in Patients With Schizophrenia
Schizophrenia
Primary: Time to Relapse or Impending Relapse — NA; 99 Days — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=305 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
Schizophrenia · Schizoaffective Disorder
Primary: Substantial Clinical Deterioration Measured by Psychotic Symptoms — 1.8; 2.0 units on a scale
N/A N=139 Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
Schizophrenia Relapse
Primary: Number of Participants With Relapse — 130 Participants
Phase 3 N=764 Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Schizophrenia
Primary: Time to First Relapse Event — 616; 603 days — p=0.0191
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 3 N=765 A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
Schizophrenia
Primary: Time From Baseline to the First Symptom Relapse During the Double-blind Phase — 92; 224 Days — p=0.0010
N/A N=126 A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Relapses in Participants — 20; 22 Participants — p=0.80
Phase 3 N=711 A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Psychotic Disorders
Primary: Mean Relapse Free Period(Risperidone LAI Versus Quetiapine) — 607; 533 days — p=<0.0001
Phase 3 N=392 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Dementia-related Psychosis
Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023
Phase 3 N=201 An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
Schizophrenia
Primary: Double Blind (DB) Phase: Median Time to Relapse — NA; 49.0 Days
Phase 4 N=489 Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
Schizophrenia
Primary: Time to First Hospitalization — 530.6; 613.7 days
Phase 4 N=110 Antipsychotic Discontinuation in Alzheimer's Disease
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Phase 3 N=506 A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Schizophrenia
Primary: Time to Relapse During the Double-Blind Phase — 395.0; NA Days
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
Phase 4 N=31 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088
N/A N=176 Brief Group Psychoeducation for Schizophrenia
Schizophrenia
Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59
N/A N=59 Cognitive Rehabilitation in Schizophrenia
Cognitive Impairment · Schizophrenia
Primary: Wisconsin Card Sort Percent Perseverative Errors (Standard Score) — 87.54; 87.88; 91.80 standard score units — p=<.97
Phase 4 N=50 Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
Bipolar Disorder
Primary: Number of Relapse-related Events Normalized to Unit Time — 5.34; 6.26 Events/month
Phase 4 N=126 Sustaining Remission of Psychotic Depression
Psychotic Depression
Primary: Number of Subjects at Risk of Relapse During the Randomized Phase. — 13; 34 Participants
Phase 3 N=838 A Study of Paliperidone Palmitate 6-Month Formulation
Schizophrenia
Primary: Time to Relapse During the Double-Blind (DB) Phase — NA; NA Days
Phase 3 N=667 A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
Schizoaffective Disorder
Primary: Double-blind: Percentage of Participants Who Experienced Relapse — 15.2; 33.5; 11.5; 32.9 percentage of participants — p=<0.001
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 4 N=219 Switching Medication to Treat Schizophrenia
Schizophrenia
Primary: Number Who Discontinued Medication Within First 6 Study Months — 11; 23 participants
Phase 3 N=524 Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Schizophrenia
Primary: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) — 644.50; 677.50 Days — p=0.612
Phase 3 N=67 A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
Mania (Neurotic)
Primary: Rate of Relapse — .11; .13 Proportion of Participants
Phase 3 N=123 A Physical Dependence Study in Schizophrenia
Schizophrenia
Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170
Phase 4 N=26 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01
Phase 3 N=88 Aripiprazole Once-monthly in Patients With Schizophrenia
Schizophrenia
Primary: Safety and Tolerability — 65 number of events
Phase 4 N=450 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Schizophrenia
Primary: Time to First Treatment Failure — 416; 226 Days
N/A N=30 Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Patient Noncompliance
Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days